<DOC>
	<DOCNO>NCT00913263</DOCNO>
	<brief_summary>The primary objective evaluate efficacy single dose Liproca Depot patient localized prostate cancer . Primary efficacy variable proportion patient show PSA nadir . 24 Caucasian men , mean age inclusion 68.4 year , localized prostate cancer inject ready make paste include 600 mg 2-hydroxyflutamide ( Liproca Depot ) site prostate tumour localize . The patient monitor prostate-specific antigen ( PSA ) maximum 6 month progression within time period . The primary endpoint show interesting result high success rate ( 83 % ) , i.e . proportion patient ( Responders ) reach plasma PSA nadir .</brief_summary>
	<brief_title>An Efficacy Safety Study With Licroca Depot , Controlled Release Product , Injected Into Prostate</brief_title>
	<detailed_description>Patients localized prostate cancer follow progression maximum 24 week single injection one lobe 2-8 mL ready-made paste ( correspond 400-1600 mg 2-Hydroxyflutamid ) . Progression define increase PSA &gt; 25 % baseline on-treatment nadir.Among 24 patient primary endpoint , plasma PSA nadir , reach 20 patient ( Responders ) . Efficacy measure primarily PSA nadir , secondly time PSA nadir prostate volume change . Safety monitor throughout whole study period .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hydroxyflutamide</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<criteria>1 . Age ≥ 45years 2 . Histologically confirm localized prostate cancer ( T1T2 ) , predominantly one side peripheral zone , verify biopsy . 3 . PSA value &lt; 20 ng/ml within 6 week enrolment . 4 . Gleason score ≤ 3+4 diagnostic biopsy 5 . Adequate renal function : Creatinine &lt; 1.5 time upper limit normal . 6 . Adequate hepatic function : ASAT , ALAT ALP &lt; 1.5 time upper limit normal . 7 . Negative dipstick bacturia . 8 . Patient must ability cope study procedure return schedule visit include follow visit . 1 . Previous ongoing hormone therapy prostate cancer . 2 . Ongoing previous therapy ( within3 month ) finasteride dutasteride . 3 . Ongoing previous invasive therapy benign prostate hyperplasia ( TURP , TUMT ) . 4 . Symptoms sign acute prostatitis . 5 . Symptoms sign ulceric proctitis 6 . Severe micturation symptom ( IPSS &gt; 17 ) 7 . Concomitant systemic treatment corticosteroid , immunomodulating agent . 8 . Known immunosuppressive disease ( e.g . HIV , insulin dependent diabetes ) . 9 . Simultaneous participation study involve market authorize drug participate study within last 12 month prior start study treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Prostate cancer</keyword>
</DOC>